SPPI Spectrum Pharmaceuticals Inc.

19.67
+5.21  (36%)
Previous Close 14.46
Open 19.22
Price To book 9.28
Market Cap 1844203967
Shares 93,757,192
Volume 19,611,011
Short Ratio 5.12
Av. Daily Volume 1,441,397

SEC filingsSee all SEC filings

  1. 8-K - Current report 171142746
  2. 8-K - Current report 171136772
  3. 8-K - Current report 171128589
  4. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 171109016
  5. 8-K - Current report 171108989

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 initiation announced March 30, 2017 with preliminary data due released October 18, 2017 - ORR 73%.
Poziotinib
Non-small cell lung cancer (NSCLC)
CRL received October 9, 2009. Approved April 29, 2011.
FUSILEV
Colorectal cancer
CRL received July 5, 2009.
ZEVALIN
Non-Hodgkin’s lymphoma
CRL October 23 2015. Approved March 15 2016.
EVOMELA (melphalan) for Injection
Conditioning treatment prior to autologous stem cell transplant for patients with multiple myeloma
Phase 2 initiated March 2016. Ongoing.
Poziotinib
Breast cancer
Failed to meet primary endpoint in Phase 3 trial - Apr 2012. PDUFA date December 11 2016. Advisory Committee Meeting September 14 2016 voted 14 - 0 against approval. CRL issued November 17, 2016. New Phase 3 trial initiation announced August 14, 2017.
QAPZOLA - Apaziquone
Bladder cancer
Phase 3 completion of enrollment announced August 1, 2017 with top-line data due 1Q 2018.
SPI-2012 (ROLONTIS)
Chemotherapy-Induced Neutropenia
Approved July 7, 2014.
Belinostat
Peripheral T-Cell Lymphoma cancer

Latest News

  1. What Happened in the Stock Market Today
  2. Why Spectrum Pharmaceuticals Stock Jumped Higher Today
  3. Four Biotech And Health Care Breakouts
  4. Investors Race to Buy Spectrum Pharmaceuticals, Inc. (SPPI) Shares; Here’s Why
  5. Harry Boxer’s three biotech-stock breakouts to watch
  6. Spectrum Shares Surge on Data for Lung Cancer Drug -- Biotech Movers
  7. Why Spectrum Pharmaceuticals Shares Are Surging
  8. Today's Research Reports on Trending Tickers: Array BioPharma and Spectrum Pharmaceuticals
  9. Spectrum Pharmaceuticals Highlights Poziotinib Data in Non-Small-Cell Lung Cancer (NSCLC) Presented at the 18th IASLC World Conference on Lung Cancer in Japan
  10. Stonegate Capital Partners Updates Coverage on Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI)
  11. Spectrum Pharmaceuticals Announces Agreements to Exchange $69.5 Million in Principal Amount of Its 2.75% Convertible Senior Notes Due 2018 for Common Stock and Cash
  12. ETFs with exposure to Spectrum Pharmaceuticals, Inc. : October 9, 2017
  13. Top 4 Small-Cap Stocks for 2017
  14. 3 Biotech Stocks That Soared This Week: Are They Buys?
  15. ETFs with exposure to Spectrum Pharmaceuticals, Inc. : September 29, 2017
  16. Today's Research Reports on Trending Tickers: MannKind Corporation and Spectrum Pharmaceuticals
  17. Spectrum Pharmaceuticals Provides Update on At-The-Market Facility
  18. Here's Why Spectrum Pharmaceuticals, Inc. Is Surging Today
  19. Spectrum Pharmaceuticals Highlights Poziotinib Data in Lung Cancer to be Presented in an Oral Presentation at the 18th IASLC World Conference on Lung Cancer in Yokohama, Japan, October 15-18, 2017
  20. Spectrum Pharmaceuticals to Present at Two Upcoming Investor Conferences in September

SEC Filings

  1. 8-K - Current report 171142746
  2. 8-K - Current report 171136772
  3. 8-K - Current report 171128589
  4. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 171109016
  5. 8-K - Current report 171108989
  6. 424B5 - Prospectus [Rule 424(b)(5)] 171009426
  7. 8-K - Current report 171009405
  8. 10-Q - Quarterly report [Sections 13 or 15(d)] 171009311
  9. 8-K - Current report 171004889
  10. CT ORDER - Confidential treatment order 17961424